The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
Anemia, Atherosclerosis, End-Stage Renal Disease
About this trial
This is an interventional treatment trial for Anemia focused on measuring Anemia, atherosclerosis, End-stage renal disease, Erythropoietin, Hemodialysis, Oxidative stress, Pro-inflammation
Eligibility Criteria
Inclusion Criteria: On HD thrice a week at our HD unit for more than three months Informed consent The dose of EPO and iron supplement is stationary in the previous one month No taking acetylcysteine in previous one month No using vitamin E-bonded dialysis membrane Exclusion Criteria: Severe liver disease (AST or ALT >40 IU/L), proven malignancy, and severe cardiovascular disease (proved by cardiac catheter or echography examination) Active infection or hospitalization in previous one month Clinically significant bleeding episode in previous one month Taking vitamin C, vitamin E or other known antioxidants.
Sites / Locations
- Far Eastern Memorial Hospital